Dr Wagh committed to transforming pharmaceutical manufacturing
Mumbai’s Supriya Lifescience Ltd has acquired approval from Brazil’s health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, which is a major step in growing its product range in Latin America http://gov.br.
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing https://www.bseindia.com/.
“Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil,” said Dr Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd https://www.nseindia.com/.
“Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin,” he said on 9 Dec http://who.int.
It is set to tap into the fast-growing LATAM market. The company’s continued focus on innovation, regulatory compliance, and its mission to make high-quality healthcare accessible globally positions it as a key player in the international pharmaceutical landscape https://sbi.com.in/.
Supriya Lifescience, a world-renowned producer of active pharmaceutical ingredients, was founded in 1987and has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. Headquartered in Mumbai, the company has facility in in Khed, District Ratnagiri and has globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Fiinews.com
